Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptodornase is an enzyme produced by certain strains of hemolytic Streptococci, notably *Streptococcus equisimilis*. It acts as a deoxyribonuclease (DNase), catalyzing the depolymerization of deoxyribonucleoproteins in dead cells and pus, thereby liquefying these components in wounds. This mucolytic action facilitates the removal of clotted blood, fibrinous or purulent accumulations from surface lesions or closed body cavities. Streptodornase is often used in combination with another enzyme, streptokinase; together they are applied topically or instilled to treat conditions involving blood clots and purulent exudates such as hemothorax, hematomas, chronic suppurations, and sometimes for respiratory tract infections. The mechanism involves stimulating DNase I activity to break down DNA-rich material in necrotic tissue[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on streptodornase.